Novartis provides updates on its leading research and development (R&D) pipeline
Novartis R&D Day 2012 held on November 8th in Cambridge, MA, (USA) is an Investor event with senior Novartis executives discussing developments in research and development (R&D) across its divisions including Oncology and Pharmaceuticals.
Novartis International BioCamp 2012
Novartis International BioCamp highlights global R&D reach to meet patient needs in emerging markets.
Swiss Graduate Barometer 2012 – Handelszeitung
Novartis ranked most popular employer in healthcare by Swiss students in Swiss Graduate Barometer
Chairman Daniel Vasella, M.D.: spending more doesn’t always lead to better care
A recent comparison of world health shows that countries that spend less often have higher quality care, writes Daniel Vasella, chairman of Novartis.
Africa’s double burden
In the past, fast-spreading diseases were the continent’s greatest threat—malaria, tuberculosis, HIV, measles, diarrhea, polio and other communicable diseases. These problems remain real and serious. But today, Africa’s future may depend even more on battling chronic diseases that aren’t spread between people, such as cancer, diabetes and cardiovascular disease.
Africa's growing need for medical expertise
Africa is on the rise. The evidence is everywhere. In a 2011 report, the World Bank declared that “Africa could be on the brink of an economic take-off.” The World Health Organization (WHO) 2011 African Regional Health Report revealed that Africa has made significant progress in the battle against many communicable diseases, including river blindness, malaria, leprosy and measles, among others.
The two Africas
In May 2000, The Economist ran a cover story on Africa under the headline, “The Hopeless Continent.” The article detailed violence and disease ravaging the region — the cover pictured a fighter with a weapon on his shoulder framed by an African map.
Novartis works for patients with rare diseases
From pioneering Novartis medicines used by patients worldwide to treat rare forms of cancer to potential medical breakthroughs now undergoing clinical testing, our commitment to rare diseases has never been stronger. Underscoring that commitment, Novartis headquarters in Basel, Switzerland, will host the RE(ACT) Congress, the first international congress on research of rare and orphan diseases, from February 29 to March 2.
Delivery of child-friendly antimalarial hits the 100 million mark
In 2009, Novartis and MMV launched the first child friendly artemisinin-combination therapy (ACT), meeting the calls from UNICEF and the WHO for age-appropriate medicines. Three years after launch, deliveries of this child-friendly antimalarial hit the 100 million mark.
Novartis continues fight to help end leprosy
Novartis announced today that it will extend its collaboration with the World Health Organization and others to end leprosy.
The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.